{
  "docId": "019de076-883a-72e4-86fb-18270cd4f977",
  "docSlug": "5c729b46407684473082dcb9c39fe3fc",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 25,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a patient MRI, a schematic of the PDX study design, a line chart showing tumor volume over time, and photographic evidence of tumor size reduction.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-883a-72e4-86fb-18270cd4f977/10",
  "deckHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977",
  "deckJsonHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977.json",
  "deckAnchorHref": "/decks/019de076-883a-72e4-86fb-18270cd4f977#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.21,
        "x": 0.64,
        "y": 0.57
      },
      "kind": "chart",
      "text": "Delta in Tumor Volume (mm3) over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a577a03-99d9-496c-964b-664294f98b46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.34,
        "x": 0.64,
        "y": 0.245
      },
      "kind": "diagram",
      "text": "PDX study workflow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab13d403-1596-4dae-9daa-a74e9c44c570",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.03,
        "y": 0.59
      },
      "kind": "disclaimer",
      "text": "a. The cholangiocarcinoma foundation, cholangiocarcinoma.org/key-statistics",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0a3d317-ca61-4de2-a40a-92fd816156a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.26,
        "x": 0.37,
        "y": 0.245
      },
      "kind": "image",
      "text": "MRI scan of CCA tumor",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f3f45f0-03d2-4b10-ac74-cad774bc23cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.11,
        "x": 0.87,
        "y": 0.57
      },
      "kind": "image",
      "text": "Tumor size comparison (Vehicle vs NXP800)",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73b0f8ad-d648-4b4a-b270-e24e376667c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.03,
        "y": 0.245
      },
      "kind": "list",
      "text": "Cholangiocarcinoma (CCA) is a lethal malignancy with poor prognosis arising from the biliary tree. Approx. 10,000 new cases/year in the US",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85327c4b-8ef1-4d07-b517-cefe483daabb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Substantial Antitumor Activity in Cholangiocarcinoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ccf7e71-9d0b-41e4-8b9e-084ee54200c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Additional potential development opportunities",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1d29d6e-7720-4f0d-a8b0-86f13dbad929",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "9ba638df-332a-4b15-a2bf-a27225c05ef4",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document highlights the potential market opportunity for NXP800 and NXP900 in multiple cancers.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}